Pharmacological management of obesity: Current landscape and emerging therapies.

Narrative review

“In this narrative review, we will explore the rapidly evolving field of obesity pharmacotherapy, starting with a brief history of withdrawn antiobesity medications, then exploring the currently approved drugs that form the cornerstone of modern obesity care, and finally moving into the exciting future pipeline of therapies that aim to re-engineer metabolic regulation in innovative ways.”

Six medications are currently approved by the U.S. Food and Drug Administration for long-term obesity management.

“Currently, six medications (Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Semaglutide, and Tirzepatide) are approved by the U.S. Food and Drug Administration for long-term obesity management and among these, glucagon-like peptide receptor agonists have revolutionized the therapy.”

Obesity is recognized as a chronic, multifactorial, and progressive disease rather than mere excess body weight.

“Obesity is now recognized as a chronic, multifactorial, and progressive disease as opposed to mere excess of body weight.”

New dual and triple combination therapies are in the pipeline for better efficacy and metabolic outcomes.

“It has new dual and triple combinations such as CagriSema, Survodutide, and Retatrutide for better efficacy and metabolic outcomes, as well as long-acting and oral formulations, which will improve adherence and accessibility.”